Kennedy's HHS Nomination Sparks Mixed Reactions in Medtech Sector

 
• By Elizabeth Orr

Robert F. Kennedy Jr.'s nomination to lead the US Department of Health and Human Services has generated both cautious optimism and concerns in the medtech sector, with concerns including a less science-based regulatory environment and potential user fee cuts.

Robert F. Kennedy Jr. holds a campaign rally in January 2024
(Bryan Regan/Shutterstock)

Robert F. Kennedy Jr., nominated by President-Elect Donald Trump on 14 November to lead the Department of Health and Human Services, has expressed controversial views on several regulated industries. He’s promised to revisit federal vaccine recommendations, take fluoride out of public water, and remove dyes and other additives from the food supply. But on medical devices, the former environmental lawyer has been uncharacteristically mum.

Medtech industry insiders contacted by Medtech Insight were unaware of any specific views Kennedy has expressed around medtech. His core...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medtech Insight

More from Policy & Regulation

European Medtechs Reiterate Opposition To Reciprocal Tariffs On US Imports

 
• By Ashley Yeo

EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.